This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biospectra, Inc. and BioSpectra Canada, Ltd completed the acquisition of Polydex Pharmaceuticals Limited (OTCPK:POLX.F). CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2023 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2023 CI
Biospectra, Inc. and BioSpectra Canada, Ltd entered into an agreement to acquire Polydex Pharmaceuticals Limited (OTCPK:POLX.F) for $6.9 million. CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022 CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Revenue $858,089 MT
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Loss $-0.11 MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended July 31, 2022 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2022 CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Posts Q1 Revenue $1.2M MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
Polydex Pharmaceuticals Limited Enters into an Agreement with Termanox Water Treatment Solutions for A Novel Use of Its Native Dextran Product CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021 CI
Polydex Pharmaceuticals : Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q2 Revenue $1.34M MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2021 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2021 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2020 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended October 31, 2019 CI
Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2019 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2019 CI
Polydex Pharmaceuticals Limited Announces Executive Changes CI
Polydex Pharmaceuticals Limited Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended Oct. 31, 2018 CI
Polydex Pharmaceuticals Limited Announces Earnings Results for the Second Quarter and Six Months Ended July 31, 2018 CI
Polydex Pharmaceuticals Limited Announces Earnings Results for the First Quarter Ended April 30, 2018 CI
Chart Polydex Pharmaceuticals Limited
More charts
Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company's products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.
More about the company
  1. Stock Market
  2. Equities
  3. POLXF Stock
  4. News Polydex Pharmaceuticals Limited
  5. Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Posts Q1 Revenue $1.2M